Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

59 60 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

How Is The Market Feeling About AstraZeneca? ↗

February 17, 2025

Via Benzinga

2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 ↗

February 15, 2025

Via The Motley Fool

AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients ↗

February 14, 2025

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025.

Via Benzinga

Is NASDAQ:AZN suited for quality investing? ↗

February 14, 2025

A fundamental analysis of (NASDAQ:AZN): Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) a Strong Candidate for Quality Investing?

Via Chartmill

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗

February 13, 2025

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Via Benzinga

Why AstraZeneca Topped the Market on Thursday ↗

February 06, 2025

Via The Motley Fool

AstraZeneca Unusual Options Activity ↗

February 06, 2025

Via Benzinga

Earnings Scheduled For February 6, 2025 ↗

February 06, 2025

Via Benzinga

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

February 13, 2025

Via Benzinga

Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades' ↗

February 12, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 11, 2025

Via Benzinga

AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript ↗

February 06, 2025

AZN earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

AstraZeneca Bounds Higher On Fourth-Quarter Beat, Upbeat Guidance ↗

February 06, 2025

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Via Investor's Business Daily

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China ↗

February 06, 2025

AstraZeneca's Q4 revenue beat estimates at $14.89 billion, with strong oncology sales. China sales dipped 1%, while FY25 guidance forecasts solid growth.

Via Benzinga

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

Q4 Earnings Scorecard & Analyst Reports For Alphabet, Blackstone & KLA ↗

February 03, 2025

Today's Research Daily features a real-time scorecard of the Q4 earnings season and new research reports on 16 major stocks, including Alphabet Inc., Blackstone Inc., and KLA Corporation, as well as a...

Via Talk Markets

Topics Stocks / Equities

AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant ↗

February 03, 2025

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing concerns over NHS drug pricing and industry tensions.

Via Benzinga

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗

January 29, 2025

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Via Benzinga

Topics Government

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗

January 28, 2025

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

Via Benzinga

AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth ↗

January 24, 2025

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines globally by 2030.

Via Benzinga

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside ↗

January 22, 2025

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.

Via Benzinga

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗

January 21, 2025

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data.

Via Benzinga

Beyond Rigetti: Top 3 Quantum Computing Stock Picks

January 21, 2025

Quantum computing is in its early stages, but investors may benefit from the incremental progress being made by these three companies

Via MarketBeat

Topics Artificial Intelligence

3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever ↗

January 21, 2025

Via The Motley Fool

AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline ↗

January 17, 2025

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives and focusing on innovative cancer drugs.

Via Benzinga

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma ↗

January 17, 2025

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

Via Benzinga

3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices ↗

January 15, 2025

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

Headline News about AstraZeneca PLC - American Depositary Shares

Starting at $3.75/week.

Subscribe Today